GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Net Debt Paydown Yield %

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Net Debt Paydown Yield % : 0% (As of Jun. 09, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Enzon Pharmaceuticals's Net Debt Paydown Yield % was 0%.


Enzon Pharmaceuticals Net Debt Paydown Yield % Historical Data

The historical data trend for Enzon Pharmaceuticals's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Net Debt Paydown Yield % Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enzon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enzon Pharmaceuticals's Net Debt Paydown Yield %

For the Biotechnology subindustry, Enzon Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's Net Debt Paydown Yield % falls into.



Enzon Pharmaceuticals Net Debt Paydown Yield % Calculation

Enzon Pharmaceuticals's Net Debt Paydown Yield % for the quarter that ended in Mar. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( - )/7.0132797
=0 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Enzon Pharmaceuticals  (OTCPK:ENZN) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Enzon Pharmaceuticals Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121